Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma
“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Adding abemaciclib to endocrine therapy led to a significant reduction in invasive disease recurrence versus endocrine therapy alone in HR-positive, HER2-negative early-stage breast cancer, according to the results of a new study. “This is a very important trial, and the findings will change practice,” said Giuseppe Curigliano, MD, PhD.
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
For patients with recurrent ovarian cancer progressing within 6 to 12 months after their last platinum line, a combination of trabectedin and pegylated liposomal doxorubicin (PLD) did not demonstrate superiority over a combination of carboplatin and PLD.
XMT-1536 is an antibody-drug conjugate that targets the sodium-phosphate cotransporter NaPi2b, which is commonly expressed in solid tumors such as high-grade serous ovarian cancer. Treatment with XMT-1536 results in an overall response rate of 34% in patients with advanced disease; antitumor activity is positively correlated with a higher NaPi2b expression.
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Results from the PAOLA/ENGOT-ov25 study indicate that adding olaparib to maintenance bevacizumab after first-line platinum-based chemotherapy for patients with newly diagnosed high-grade ovarian cancer improves second progression-free survival and time to second subsequent therapy or death.
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab as first-line treatment for patients with newly diagnosed stage III or stage IV ovarian cancer did not improve progression-free survival or overall survival but exploratory subgroup analyses are ongoing.
Page 1 of 3
Results 1 - 10 of 25
Results 1 - 10 of 25